JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliance Certificate For The Period Ended 31 March, 2020.
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Compliance Certificate, for the half year ended 31st March, 2020, signed by Compliance Officer of the company and the Authorized Representative of Share Transfer Agent. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- NANDITA SINGHDesignation :- Company Secretary and Compliance Officer JAGSONPAL PHARMACEUTICALS LTD. - 507789 - JAGSONPAL PHARMACEUTICALS LIMITED- Reply To Clarification Sought By National Stock Exchange Of India Ltd On Price Movement.
With reference to the clarification sought by National Stock Exchange of India Ltd, please note that the Company is in compliant with all the necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and all the material information/event which have bearing on the operation or performance of the Company which includes all price sensitive information are disseminated to the stock exchange well within the time by the Company. Further, please note that we do not have any information or announcement (including pending announcement) which in our opinion may have a bearing on the price behavior of the Scrip. Therefore the movement in the Share price of the Company is purely due to Market Conditions and absolutely market driven and management of the Company is in no way connected with any such movement of price. The reply has also been submitted to the National Stock Exchange of India Limited. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - JAGSONPAL PHARMACEUTICALS LIMITED- Reply To Clarification Sought By National Stock Exchange Of India Ltd On Price Movement.
With reference to the clarification sought by National Stock Exchange of India Ltd, please note that the Company is in compliant with all the necessary disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 and all the material information/event which have bearing on the operation or performance of the Company which includes all price sensitive information are disseminated to the stock exchange well within the time by the Company. Further, please note that we do not have any information or announcement (including pending announcement) which in our opinion may have a bearing on the price behavior of the Scrip. Therefore the movement in the Share price of the Company is purely due to Market Conditions and absolutely market driven and management of the Company is in no way connected with any such movement of price. The reply has also been submitted to the National Stock Exchange of India Limited. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Closure of Trading Window
The Trading Window for dealing in securities of Jagsonpal Pharmaceuticals Limited ("the Company") shall remain closed for Designated Persons and their immediate relative(s) with effect from i.e. April 01, 2020 till the end of 48 hours after the declaration of financial results for the Quarter and year ended 31st March, 2020. Jagsonpal Pharmaceuticals Ltd - 507789 - Unaudited Financial Results
Unaudited financial results Jagsonpal Pharmaceuticals Ltd - 507789 - Outcome Of Board Meeting
Outcome of Board Meeting. The meeting was commenced at 12:00 Noon and concluded at 16:05. Jagsonpal Pharmaceuticals Ltd - 507789 - Board Meeting Intimation for For Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2019.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2020 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2019. Jagsonpal Pharmaceuticals Ltd - 507789 - Shareholding for the Period Ended December 31, 2019
Jagsonpal Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In Compliance with Regulation 74 (5) of SEBl (Depositories and Participants) Regulations, 2018 we are forwarding herewith a copy of the Certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended 31st December, 2019.